Newport News, VA – According to filings with the U.S. Securities and Exchange Commission, ivWatch is raising $20,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Gary Warren played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ivWatch
ivWatch, LLC is a medical device and biosensor company focused on improving the safety and effectiveness of intravenous (IV) therapy. IV therapy is a basic yet critical component of care in hospital and outpatient settings, but it has a high failure rate. Continuous monitors exist to keep track of patients heart and blood oxygen levels. Until now, no technology has been available to continuously monitor the health of a patients IV site, and whether drugs or fluids are being delivered through the vein or leaking into the tissue. The ivWatch Model 400 is an FDA-cleared device to help clinicians monitor the status of a patients IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. ivWatch is transforming IV therapy by improving patient care and safety and offering health care providers a much-needed, reliable and cost-effective solution for continuously monitoring peripheral IVs.

To learn more about ivWatch, visit http://www.ivwatch.com/

Contact:
Gary Warren, President and Chief Executive Officer
855-489-2824
gary.warren@ivwatch.com
https://www.linkedin.com/in/gary-warren-230a0a2/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved